Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 4,948 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Con el envejecimiento de la población general, el número de pacientes con epilepsia de inicio tardío crece constantemente.
Why it matters
This review describes epilepsy as a frequent comorbidity in early-onset Alzheimer's disease and notes that late-onset epilepsy may sometimes be the first clinical sign of Alzheimer's disease. It addresses recognition of seizures in the Alzheimer's spectrum rather than a cure or prevention.
-
Nößler: Selten hat die Neuanführung eines Arzneimittels so ein großes Medienecho ausgelöst wie jüngst der Markteintritt von Lecanemab und jetzt die Zulassung von Donanemab.
Why it matters
This podcast transcript discusses whether lecanemab and donanemab are genuine advances or hype, and whether they might even pose a risk to care. It does not report new trial results or provide evidence on treating, curing or preventing Alzheimer's disease.
-
Sequencing revealed a biallelic SORL1 splice donor variant (c.1211 + 1G > A).
Why it matters
This study found a biallelic SORL1 splice donor variant in a patient and presents evidence that SORL1 may be a recessive disease-causing gene for a form of complicated hereditary spastic paraplegia. It concerns hereditary spastic paraplegia rather than Alzheimer's disease, and does not address treating, curing or preventing Alzheimer's.
-
(1) GARS-AIRS-GART is an important candidate gene in studies of Down syndrome (DS)-related Alzheimer's disease (AD), due to its chromosomal localization (21q22.1) in the Down syndrome critical region, involvement in de novo purine biosynthesis, and over-expression in DS brain.
Why it matters
Using bioinformatics, this study identified a transcription factor, LBP-1c/CP2/LSF, as a candidate that may influence expression of the GARS-AIRS-GART gene in Down syndrome-related Alzheimer's disease. It is a computational analysis and provides no treatment, cure or prevention.
-
In recent years, it has been possible for patients with Down syndrome to live longer with advanced medical treatment and social support.
Why it matters
Among 30 children with Down syndrome, brain SPECT showed hypoperfusion in 11 cases, and epilepsy was more common in those with hypoperfusion. This was a small pediatric imaging study and did not test any treatment, cure or prevention for Alzheimer's disease.
-
The diagnostic significance of tau proteins in cerebrospinal fluids (CSF) has been described in many cases of dementia of Alzheimer type (AD).
Why it matters
This study examined whether cerebrospinal fluid tau and amyloid beta markers could help tell apart corticobasal degeneration and progressive supranuclear palsy, conditions that are clinically and pathologically difficult to distinguish. It is a diagnostic marker study and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Physical Examination.—Physical examination revealed that the patient was well developed, but poorly nourished, with an appearance of chronic illness.
Why it matters
This is a 1932 case report of a fatal case of systemic blastomycosis, describing the patient's appearance of chronic illness. It has no relevance to treating, curing, or preventing Alzheimer's disease.
-
The accumulation of tau proteins in the brain contributes to the therapeutic challenges faced by patients with Alzheimer’s disease, frontotemporal dementia, and other neurodegenerative disorders.
Why it matters
In preclinical work using patient-derived organoids and animal models, suppressing KCTD20 with siRNA or antisense oligonucleotide increased lysosomal exocytosis, reduced tau aggregation and increased neuron survival. This is early laboratory research, and the authors describe it as a new preclinical modality rather than a proven treatment.
-
Alzheimer disease is one of the causes of dementia that could make the patient lose their memories until they unable to do normal activities.
Why it matters
This laboratory work compared two antibody labelling methods, horseradish peroxidase and biotin, for use in an ELISA test that measures the Alzheimer's-related protein Amyloid-β42. It is a technical methods study about test reagents and does not test any treatment, prevention or cure in patients.
-
Down syndrome (DS), caused by trisomy of chromosome 21, exhibits significant phenotypic variability, including intellectual disability, early-onset Alzheimer disease (AD), congenital heart defects (CHDs), haematological malignancies, and immune dysregulation.
Why it matters
This review describes genetic variants, including in APP, BACE2, APOE, and PICALM, that contribute to Alzheimer's disease risk in people with Down syndrome. It highlights the complexity of genotype-phenotype relationships and the potential for precision medicine, but does not report a treatment or cure.
-
Here, new phenoxide derivatives of diisopropyl flourophosphate for reaction with Lewis basic sites on acetyl cholinesterase (AChE) were designed.
Why it matters
This work designed and modeled new chemical derivatives intended to inhibit acetylcholinesterase and raise acetylcholine levels. It is computational and docking work only, with no testing in animals or people, so it does not establish any treatment, cure or prevention for Alzheimer's disease.
-
Intersectin is an evolutionarily conserved multifunctional adaptor protein with multifunctional domains.
Why it matters
This review describes the structure and roles of the protein intersectin in endocytosis and exocytosis and its possible links to neurodegenerative diseases. It is a summary of existing knowledge and does not test any treatment, cure or prevention for Alzheimer's disease.
-
Little is known about the chronic sequelae of isopropanol ingestion.
Why it matters
This single case report describes a patient who consumed isopropyl alcohol for at least 17 years and developed cerebellar dysfunction and dementia among other problems. It is a case report about chronic isopropanol ingestion, not about treating, curing or preventing Alzheimer's disease.
-
An extra copy of the amyloid precursor protein gene (APP) is present in Down syndrome (DS) and APP duplication (APPdup), increasing the risk of Alzheimer disease (AD) and cerebral amyloid angiopathy (CAA).
-
16/100
Plasma p-tau217 concentrations were positively associated with plasma TNF- (Kendalls {tau} = 0.339; P < .001) and IL-6 (Kendalls {tau} = 0.310; P < .001) concentrations.
Why it matters
Some blood donors had higher levels of a tau protein marker (p-tau217) than expected, and these higher levels were linked to markers of inflammation. The researchers say it is unclear whether these elevations are clinically meaningful, so this is an early finding that needs confirmation and does not show any treatment or prevention.
-
16/100
Simulation results were benchmarked against real-world population estimates, over a wide range of demographic and genetic parameters.
Why it matters
This study used simulation to examine how family history can help distinguish inherited from non-inherited forms of ALS, not Alzheimer's disease. It has no direct implications for treating, curing, or preventing Alzheimer's disease.
-
IntroductionFrontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials.
Why it matters
This study found that passive smartphone data, such as step count and battery use, was feasible to collect and reflected disease severity in people with frontotemporal lobar degeneration. It is early work on remote monitoring tools and does not test any treatment.
-
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder whose genetic architecture and underlying molecular mechanisms remain incompletely understood, particularly in sporadic disease.
Why it matters
This genetic study of ALS, not Alzheimer's disease, found that predicted blood DNA methylation at certain sites was associated with ALS risk. It is basic research into ALS biology and has no direct implications for treating or preventing Alzheimer's disease.
-
ObjectiveEffective strategies to prevent Alzheimers disease and related dementias (ADRD) are limited.
Why it matters
In a database study, older adults who took varenicline for smoking cessation had a lower risk of developing Alzheimer's disease and related dementias than those who used nicotine replacement therapy. This is observational evidence only, and the authors call for further research before varenicline could be considered for prevention.
-
16/100
We focus on neuroinflammation in disorders associated with frontotemporal lobar degeneration (FTLD).
Why it matters
This study found that a brain chemical marker, myo-inositol, was elevated in a disease-affected brain region in people with frontotemporal lobar degeneration and was linked to inflammation markers and worse cognitive scores. It is research into measuring neuroinflammation, not a treatment or cure.
-
Neuroinflammation is a principal driver of brain atrophy and cognitive decline in Alzheimers disease (AD).
Why it matters
In a small study of 49 people with mild Alzheimer's disease, a stem cell therapy called laromestrocel was linked to less brain inflammation, less brain shrinkage, and better cognitive scores compared with placebo. These are early results from a small sample, and larger trials are needed to confirm whether the treatment is safe and effective.
-
16/100
--Clinical trajectories after a diagnosis of mild cognitive impairment (MCI) vary widely, so prognostic models must account for both the timing of subsequent diagnoses and unequal follow-up.
Why it matters
This study built a model using age and a blood marker, p-tau217, to predict which people with mild cognitive impairment will develop dementia. The model worked moderately well in one group but its accuracy in a second group was uncertain, with a wide range that included near-chance results, so it is not yet ready for clinical use.
-
Alzheimer’s disease (AD) pathology including amyloid beta (Aβ) plaques and tau tangles accumulate with age in Down Syndrome (DS).
Why it matters
This postmortem brain tissue study found reduced binding of a radiotracer to nicotinic acetylcholine receptors in Down syndrome and Alzheimer's disease brains. It describes a cholinergic abnormality but tests no treatment or prevention.
-
IntroductionGenetic studies have shown the APOL1 variant p.N264K, also called M1, is associated with markedly lower kidney disease risk when co-inherited with the G2-risk allele.
Why it matters
This laboratory study looked at how two versions of the APOL1 gene affect cell channels when they occur together on the same chromosome. It is basic in-vitro research about kidney disease genetics, not a study of Alzheimer's disease or its treatment.
-
Gross brain findings help guide differential diagnosis, but their diagnostic value across major neurodegenerative diseases remains incompletely characterized.
Why it matters
This study found that large language models could extract gross brain findings from autopsy reports to help classify neurodegenerative diseases, with high sensitivity for PSP and MSA but low sensitivity for combined Alzheimer's and Lewy body disease. It is a diagnostic aid, not a treatment, cure, or prevention.
From across this topic
10 of the 4,930 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice
- Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration
- Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE
- Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment
- Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus
- Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease
- Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation
- Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
- The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023